Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapamycin treatment reduces CD11c<sup>+</sup> microglia and increases amyloid plaque load in 5xFAD mice.

Experimental neurology·2026
Same author

Factors associated with mortality in early stages of parkinsonism.

NPJ Parkinson's disease·2022
Same author

Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach.

NPJ Parkinson's disease·2021
Same author

Turning Back the Clock in Parkinson's Disease: Practical Recommendations for Managing Diurnal Symptom Worsening.

Journal of Parkinson's disease·2021
Same author

Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning.

Movement disorders : official journal of the Movement Disorder Society·2021
Same author

The Architecture of Contemporary Care Networks for Rare Movement Disorders: Leveraging the ParkinsonNet Experience.

Frontiers in neurology·2021

Related Experiment Video

Updated: Dec 17, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.8K

Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy.

Anna Santaella1, H Bea Kuiperij2, Anouke van Rumund3

  • 1Departments of Neurology, the Netherlands; Laboratory Medicine, Radboud university Medical Center and Donders Institute for Brain, Cognition and Behavior, the Netherlands; Center of Expertise for Parkinson & Movement Disorders, Nijmegen, the Netherlands.

Parkinsonism & Related Disorders
|June 25, 2020
PubMed
Summary
This summary is machine-generated.

Myelin basic protein (MBP) in cerebrospinal fluid effectively distinguishes Parkinson's disease (PD) from multiple system atrophy (MSA). This finding aids early diagnosis, as MBP levels are elevated in MSA compared to PD, suggesting early demyelination in MSA.

Keywords:
BiomarkersBrain-specific proteinsCerebrospinal fluidMultiple system atrophyParkinson's disease

More Related Videos

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

5.3K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.2K

Related Experiment Videos

Last Updated: Dec 17, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.8K
Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
08:17

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

5.3K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.2K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Clinical Neurology

Background:

  • Parkinson's disease (PD) and multiple system atrophy (MSA) present overlapping symptoms, complicating early diagnosis.
  • Accurate diagnosis is crucial due to differing prognoses and treatment responses for PD and MSA.

Purpose of the Study:

  • To assess the diagnostic utility of brain-specific structural proteins in cerebrospinal fluid (CSF) for differentiating PD and MSA.
  • To investigate the association between these protein levels and cognitive decline in PD and MSA patients.

Main Methods:

  • CSF samples analyzed from PD (n=55), MSA (n=22), and control (n=118) groups.
  • Measured levels of Neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), S100B, and myelin basic protein (MBP) using ELISA.
  • Correlated protein levels with cognitive decline using the Mini Mental State Examination (MMSE) over three years.

Main Results:

  • Myelin basic protein (MBP) concentrations were significantly higher in MSA patients compared to PD and controls (p < 0.005).
  • MBP demonstrated high accuracy in differentiating MSA from PD (AUC = 0.781; p < 0.001).
  • Elevated levels of MBP, GFAP, and S100B were observed in PD patients versus controls, while NSE levels did not differ significantly.

Conclusions:

  • MBP is a valuable biomarker for distinguishing between PD and MSA in early disease stages.
  • Elevated MBP in MSA suggests early demyelination and axonal damage.
  • No correlation was found between the studied proteins and cognitive decline (MMSE progression).